Closed-Loop Insulin Delivery Systems in Type 1 Diabetes: Technology Advances and Outcomes
Nagawa Jackline Irene
Department of Clinical Medicine and Dentistry Kampala International University Uganda
Email: irene.nagawa@studwc.kiu.ac.ug
ABSTRACT
Type 1 diabetes mellitus was characterized by absolute insulin deficiency requiring lifelong exogenous insulin replacement. Traditional insulin delivery methods, including multiple daily injections and conventional insulin pumps, impose substantial burdens on patients and often fail to achieve optimal glycemic control. Closed-loop insulin delivery systems, also known as artificial pancreas systems, represented a transformative technological advancement that automates insulin dosing through real-time continuous glucose monitoring feedback and algorithmic control. This review aimed to critically evaluate the technological evolution of closed-loop insulin delivery systems, assess their clinical efficacy and safety outcomes in type 1 diabetes management, and examine the biochemical and physiological principles underlying their operation. A comprehensive synthesis of peer-reviewed literature examining closed-loop system technology, control algorithms, clinical trial outcomes, and real-world implementation studies was conducted. Closed-loop systems demonstrated superior glycemic control compared to conventional therapy, with increased time in the target glucose range, reduced hypoglycemia frequency, and improved glycemic variability metrics. Hybrid closed-loop systems, which retain user input for mealtime boluses, have achieved widespread clinical adoption with robust safety profiles. Advanced control algorithms incorporating machine learning, adaptive insulin dosing, and predictive capabilities show promise for fully automated systems. However, challenges persisted regarding sensor accuracy, algorithm optimization for diverse physiological conditions, and equitable access to technology. Closed-loop insulin delivery systems represented a significant advancement in type 1 diabetes management, offering improved outcomes through automated glycemic regulation. Continued technological refinement and expanded accessibility remain essential priorities.
Keywords: Closed-loop insulin delivery, Artificial pancreas, Type 1 diabetes, Continuous glucose monitoring, Hybrid closed-loop systems.
CITE AS: Nagawa Jackline Irene (2026). Closed-Loop Insulin Delivery Systems in Type 1 Diabetes: Technology Advances and Outcomes. IAA Journal of Applied Sciences 14(1):84-89.